Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Olympus ( (JP:7733) ) has issued an announcement.
Olympus reported consolidated financial data for the third quarter of the fiscal year ending March 31, 2026, showing revenue of ¥261.0 billion and operating profit of ¥24.1 billion from continuing operations, with margins pressured versus the previous year. Profit attributable to owners of the parent for the quarter reached ¥14.2 billion, while foreign exchange provided only a modest tailwind compared with the prior year.
The company has reorganized its former Endoscopic and Therapeutic Solutions divisions into the new Gastrointestinal Solutions and Surgical and Interventional Solutions divisions, and has reallocated some corporate R&D and other expenses into these operating segments. Historical FY2025 figures have been restated to reflect the new structure and cost allocations, a move that will change segment-level profitability profiles but is intended to give investors clearer visibility into the performance of its main medical businesses.
The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2140.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.
More about Olympus
Olympus is a global medical technology company focused on endoscopic and therapeutic solutions, with a core presence in gastrointestinal and surgical markets. The group now manages these activities through the Gastrointestinal Solutions Division and the Surgical and Interventional Solutions Division to better align products, R&D and reporting with clinical and market needs.
Average Trading Volume: 3,099,279
Technical Sentiment Signal: Hold
Current Market Cap: Yen2174.2B
For detailed information about 7733 stock, go to TipRanks’ Stock Analysis page.